Diagnostic Robotics

Israel-based AI-powered population health management solutions provider Diagnostics Robotics offers care management programs that predict a patient’s health risks to offer precise treatment and improve patient outcomes. The company claims customer satisfaction has improved by 93% while costs have declined by USD 150 per member.

The program is built on engineered predictive models using data from sixty billions of claims data and around a hundred million patient visits. The proprietary program focuses on areas such as chronic care management, behavioral health, general risk and cost predictions, and personalized treatment plans for individuals. The company operates a B2B2C business model, offering services to payers, governments, providers, and employers. As of July 2022, the company had operations in the US and Israel.

Key customers and partnerships

In June 2021, the company partnered with insurance provider Blue Cross and Blue Shield of Rhode Island to provide personalized services to its members. In addition, as of June 2022, the company was working with government insurance programs Medicare and Medicaid to provide services to its members and reduce care costs effectively.

Funding and financials

The company raised USD 45 million in July 2022 in a Series B funding round led by StageOne investors, with participation from Mayo Clinic. The funds were allocated toward product development, market growth via investment in sales and marketing, and expansion to its human resources. In terms of its financial strength, the company’s revenue has tripled YoY since 2020.